Ignite Creation Date:
2025-12-24 @ 11:37 PM
Ignite Modification Date:
2026-02-27 @ 10:05 AM
Study NCT ID:
NCT06788756
Status:
RECRUITING
Last Update Posted:
2025-12-16
First Post:
2024-12-05
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
Sponsor:
Moleculin Biotech, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-03-12
Start Date Type:
ACTUAL
Primary Completion Date:
2029-08
Primary Completion Date Type:
ESTIMATED
Completion Date:
2030-08
Completion Date Type:
ESTIMATED
First Submit Date:
2024-12-05
First Submit QC Date:
None
Study First Post Date:
2025-01-23
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-15
Last Update Post Date:
2025-12-16
Last Update Post Date Type:
ESTIMATED